Premium
Permeability and Concentration of Levofloxacin in Epithelial Lining Fluid in Patients With Lower Respiratory Tract Infections
Author(s) -
Zhang Jing,
Xie Xin,
Zhou Xin,
Chen YuQing,
Yu JiCheng,
Cao GuoYing,
Wu XiaoJie,
Shi YaoGuo,
Zhang YingYuan
Publication year - 2010
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/0091270009355160
Subject(s) - levofloxacin , bronchoalveolar lavage , respiratory tract , medicine , respiratory system , respiratory tract infections , lung , anesthesia , pharmacology , antibiotics , chemistry , biochemistry
The purpose of the study was to assess the bactericidal effects of a single oral dose of levofloxacin (LVFX) by examining the concentration of LVFX in alveolar epithelial lining fluid (ELF) from patients with lower respiratory tract infections (LRTI). Forty patients with LRTI took 500 mg of LVFX and then received a fiberoptic bronchoscopic procedure randomly 1, 4, 8, 12, or 24 hours following dosing. Bronchoalveolar lavage fluid and blood were collected at the time of the bronchopulmonary procedure, and the LVFX concentration was determined. The mean peak concentrations of LVFX in plasma and ELF were achieved at 1.5 hours (4.07 mg/L) and 1 hour (3.44 mg/L), respectively. The AUC 24h samples were 50.12 mg · h/L and 34.51 mg · h/L, respectively. The permeability of LVFX, which was estimated based on the ratio of LVFX concentration in tissue fluids to that in plasma, was 0.78 on average across all time points. After a single dose of LVFX in patients with LRTI, the drug rapidly distributed into bronchopulmonary tissue, thereby suggesting this dose is capable of achieving the concentration in target organs required for bactericidal efficacy.